SOLICITATION NOTICE
B -- HPV mathematical modeling - Sole Source Justification
- Notice Date
- 6/7/2018
- Notice Type
- Presolicitation
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 23432
- Archive Date
- 7/7/2018
- Point of Contact
- Sarah Turner,
- E-Mail Address
-
KWP9@cdc.gov
(KWP9@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- Sole Source Justification The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to CHU de Québec, Université Laval, for the purchase of services related to mathematical models for human papillomavirus. The purpose of this action is to secure mathematical modeling and cost-effectiveness evaluation services. Due to the complexity of the necessary models for the Advisory Committee on Immunization Practices (ACIP), the modeling efforts require a researcher with a published model of the cost-effectiveness of nonavalent HPV vaccination in the United States, as well as general overall expertise in cost-effectiveness analyses, and experience in presenting cost-effectiveness analyses to ACIP. Given his human papillomavirus (HPV) modeling experience and overall expertise in HPV and cervical cancer, Dr. Brisson of CHU de Québec, Université Laval is the only source capable of performing this unique work in the required time frame. HPV-ADVISE, the HPV model developed by Dr. Brisson's group, is the only published HPV model that meets the immediate needs of the Advisory Committee on Immunization Practices (ACIP). Specifically, the HPV model must [1] be applicable to the United States (i.e., incorporate epidemiologic and economic data from the United States), (2) independently model all 9 HPV types in the nonavalent HPV vaccine, [3) provide estimates of vaccination impact and cost-effectiveness, [4] include the most relevant health outcomes that could potentially be averted through vaccination (cervical cancer and precancers, other anogenital cancers, oropharyngeal cancer, and genital warts), and [5] explicitly incorporate cervical cancer screening. The HPV-ADVISE model is the only existing HPV model that meets the criteria. Further, Dr. Brisson has experience in presenting cost-effectiveness analyses to ACIP. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement. THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE QUOTATIONS; however, all responses received within fifteen (15) days of the issuance of this notice will be reviewed by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Any response should be emailed to contract specialist at kwp9@cdc.gov by 22 June 2018.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/23432/listing.html)
- Place of Performance
- Address: Atlanta, Georgia, 30329, United States
- Zip Code: 30329
- Zip Code: 30329
- Record
- SN04947834-W 20180609/180607230955-c834e6c60811ec3da592712f4a89f687 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |